ArticleMolecular neurobiology2026
Nobiletin Modulates Transcriptomic and Metabolomic Alterations in Aβ42-Induced Primary Rat Astrocytes: Implications for Alzheimer's Disease.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Beta-amyloid (Aβ) aggregates interact with glial cells, particularly astrocytes, leading to altered morphology, disrupted homeostasis, and ultimately contributing to neurodegeneration in Alzheimer's disease (AD). Astrocytes, once considered passive support cells, are now recognized as active participants in neuroinflammatory and neurodegenerative cascades. Recent research has highlighted profound transcriptomic and metabolomic disturbances in astrocytes under AD pathology, implicating them as key players in disease progression. Nobiletin (NOB), a polymethoxylated flavonoid abundantly found in citrus peels, is known for its anti-inflammatory, antioxidant, and neuroprotective properties. However, its effects on the integrated transcriptomic and metabolomic landscape of Aβ42-induced primary rat astrocytes (PRAs) have not been fully elucidated. In this study, PRAs were treated with Aβ42 (4 µM) in the presence or absence of NOB (20 and 40 µM), for 50 min and 24 h, followed by high-throughput RNA sequencing and comprehensive metabolomic profiling. NOB significantly modulated several AD-associated molecular pathways, including acetate utilization, chemokine- and cytokine-mediated inflammatory signaling, and cholesterol biosynthesis. Additionally, metabolomic analysis revealed notable alterations in cytidine, guanosine, S-lactoylglutathione, and 2'-deoxycytidine. Integrated analysis of transcriptomic and metabolomic data showed that NOB influenced crucial pathways such as ABC transporters, steroid biosynthesis, and amino acid metabolism, including glycine, serine, and threonine metabolism and alanine, aspartate, and glutamate metabolism. These findings demonstrate that NOB might modulate transcriptional and metabolomic alterations induced by Aβ42 exposure in astrocytes, offering new insights into its multitargeted neuroprotective actions. This study supports the potential of NOB as a promising therapeutic candidate for mitigating astrocyte-mediated neuroinflammation and metabolic dysfunction in AD.
Indexed as
Identifiers
42274938What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.